Avai Bio FY26 net loss widens 53% to USD 1.75 million

AVANT TECHNOLOGIES INC

AVANT TECHNOLOGIES INC

AVAI

0.00
  • Avai Bio posted a net loss of USD 1.75 million, widening 53% from fiscal 2025.
  • Operating expenses slipped 3% to USD 1.48 million; revenue was no revenue.
  • Other income fell to USD 0 from USD 450,000, while other expenses more than quadrupled to USD 269,318 on higher convertible notes.
  • Cash declined to USD 23,145, while the working capital deficit widened to USD 3.3 million.
  • Net cash used in operating activities narrowed 13% to USD 1.01 million; financing cash inflows fell 23% to USD 951,936.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avai Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001740797-26-000017), on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.